Buprenorphine is a semi-synthetic opioid analgesic derived from thebaine. It is a partial mu-opioid receptor agonist and a kappa-opioid receptor antagonist. In the 5mg strength, it is primarily formulated as a sublingual tablet for the management of opioid dependence as part of a comprehensive treatment plan, including counseling and psychosocial support. It has a unique pharmacological profile that offers a ceiling effect on respiratory depression, making it safer in overdose compared to full agonists like methadone.
Adult: For Opioid Dependence (Induction): Initial dose is administered when clear, objective signs of moderate opioid withdrawal appear. Typical starting dose is 2-4 mg SL on Day 1, titrated upwards in increments of 2-4 mg to a target maintenance dose of 8-24 mg/day. A 5mg tablet is used as part of this titration/maintenance regimen. Maintenance: Once stabilized, dosing can be once daily or on alternate days (e.g., double the daily dose every 48 hours). For Pain: Not recommended at 5mg strength for pain initiation.
Note: Administer SUBLINGUALLY. Place tablet under the tongue and allow it to dissolve completely (takes 5-10 minutes). Do not chew, swallow, or crush. Do not eat or drink until the tablet is fully dissolved. For supervised consumption in OST centers, the dose is administered under direct observation.
Buprenorphine binds with high affinity and slow dissociation to mu-opioid receptors in the central nervous system. As a partial agonist, it produces a sub-maximal analgesic and euphoric effect compared to full agonists (e.g., heroin, morphine). This partial agonism creates a 'ceiling effect' on respiratory depression, enhancing safety. Its antagonistic action at kappa-opioid receptors may contribute to a lower incidence of dysphoria and psychotomimetic effects.
Pregnancy: Pregnancy Category C (US FDA). Can be used for maintenance therapy in pregnant women with opioid use disorder, as the benefits of preventing withdrawal and relapse outweigh the risks. Untreated addiction poses greater fetal risk. May cause neonatal opioid withdrawal syndrome (NOWS) if used chronically. Requires close obstetric and neonatal monitoring. Dose adjustments may be needed in the 3rd trimester.
Driving: May impair mental and/or physical abilities required for driving or operating machinery, especially during initiation and dose titration. Patients should be cautioned not to drive until they know how the medication affects them.
| Benzodiazepines (e.g., Alprazolam, Diazepam) | Profound sedation, respiratory depression, coma, and death. Combination is particularly dangerous outside supervised medical settings. | Major |
| Other CNS Depressants (Alcohol, Barbiturates, Sedative-hypnotics) | Additive CNS depression, increased risk of respiratory failure. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Clarithromycin, Grapefruit juice) | Increased buprenorphine plasma levels, leading to enhanced or prolonged effects and toxicity. | Moderate |
| CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased buprenorphine plasma levels, potentially leading to withdrawal symptoms and treatment failure. | Moderate |
| Full Opioid Agonists (e.g., Morphine, Methadone, Fentanyl) | Buprenorphine may block the effects of full agonists or precipitate withdrawal in dependent patients. | Major |
| Serotonergic Drugs (SSRIs, SNRIs, TCAs, Tramadol) | Increased risk of serotonin syndrome. | Moderate |
| Anticholinergics | Increased risk of urinary retention and severe constipation. | Moderate |
| MAO Inhibitors | Risk of severe opioid reaction (excitation, hypertension, hyperpyrexia). Contraindicated. | Major |
Same composition (Buprenorphine (5mg)), different brands: